| Published Application/Species/Sample/Dilution | Reference |
|---|
- flow cytometry; human; 1:50; loading ...; fig 2h
| Ravindranathan S, Passang T, Li J, Wang S, Dhamsania R, Ware M, et al. Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma. Nat Commun. 2022;13:6418 pubmed publisher |
- flow cytometry; human; loading ...; fig 6b, 6c
| Seitz C, Schroeder S, Knopf P, Krahl A, Hau J, Schleicher S, et al. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 2020;9:1683345 pubmed publisher |
| Li N, Quan A, Li D, Pan J, Ren H, Hoeltzel G, et al. The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer. Nat Commun. 2023;14:1986 pubmed publisher |
| Zhang B, Sun J, Yuan Y, Ji D, Sun Y, Liu Y, et al. Proximity-enabled covalent binding of IL-2 to IL-2Rα selectively activates regulatory T cells and suppresses autoimmunity. Signal Transduct Target Ther. 2023;8:28 pubmed publisher |
| Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022;609:369-374 pubmed publisher |
| Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K, et al. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal Transduct Target Ther. 2022;7:85 pubmed publisher |
| Omer B, Cardenas M, Pfeiffer T, Daum R, Huynh M, Sharma S, et al. A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunol Res. 2022;10:512-524 pubmed publisher |
| Leclercq G, Haegel H, Toso A, Zimmermann T, Green L, Steinhoff N, et al. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. J Immunother Cancer. 2022;10: pubmed publisher |
| Wang S, Sellner L, Wang L, Sauer T, Neuber B, Gong W, et al. Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies. Oncol Rep. 2021;46: pubmed publisher |
| Rousso Noori L, Mastandrea I, Talmor S, Waks T, Globerson Levin A, Haugas M, et al. P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas. Nat Commun. 2021;12:3615 pubmed publisher |
| Ho J, Wang L, Liu Y, Ba M, Yang J, Zhang X, et al. Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo. Mol Ther Methods Clin Dev. 2021;21:237-246 pubmed publisher |
| Cai J, Gao H, Zhao J, Hu S, Liang X, Yang Y, et al. Infection with a newly designed dual fluorescent reporter HIV-1 effectively identifies latently infected CD4+ T cells. elife. 2021;10: pubmed publisher |
| Muri J, Thut H, Feng Q, Kopf M. Thioredoxin-1 distinctly promotes NF-κB target DNA binding and NLRP3 inflammasome activation independently of Txnip. elife. 2020;9: pubmed publisher |
